Mirae Asset Global ETFs Holdings
SPRY icon

Mirae Asset Global ETFs Holdings’s ARS Pharmaceuticals SPRY Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$290K Sell
35,754
-113
-0.3% -$972 ﹤0.01% 2301
2026
Q1 		$286K Buy
35,867
+1,767
+5% +$16.9K ﹤0.01% 2174
2025
Q4 		$397K Buy
34,100
+438
+1% +$4.26K ﹤0.01% 2003
2025
Q3 		$336K Sell
33,662
-332
-1% -$4.76K ﹤0.01% 2052
2025
Q2 		$596K Buy
33,994
+1,234
+4% +$17.8K ﹤0.01% 1725
2025
Q1 		$412K Sell
32,760
-800
-2% -$9.63K ﹤0.01% 1965
2024
Q4 		$354K Buy
33,560
+3,327
+11% +$46.6K ﹤0.01% 2086
2024
Q3 		$438K Buy
30,233
+14,005
+86% +$167K ﹤0.01% 1983
2024
Q2 		$137K Buy
+16,228
New +$144K ﹤0.01% 2441

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's SPRY Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings reduced its ARS Pharmaceuticals (SPRY) stake by 0.32% in Q2 2026, selling an estimated $972 and leaving 35,754 shares worth $290K. The position accounts for ﹤0.01% of the portfolio, ranked #2301.

Mirae Asset Global ETFs Holdings first reported a position in SPRY in Q2 2024 and has held it in 9 quarters since. The position peaked at $596K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 35,754 shares of ARS Pharmaceuticals worth $290K as of Q2 2026.
  • Mirae Asset Global ETFs Holdings sold 113 ARS Pharmaceuticals shares in Q2 2026, an estimated $972.
  • ARS Pharmaceuticals made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #2301 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in ARS Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Mirae Asset Global ETFs Holdings's ARS Pharmaceuticals position peaked at $596K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.